Amarin Corp. Plc (AMRN)

15.96
0.52 3.30
NASDAQ : Health Technology
Prev Close 15.45
Open 15.44
Day Low/High 15.34 / 16.02
52 Wk Low/High 11.78 / 23.91
Volume 2.88M
Avg Volume 7.79M
Exchange NASDAQ
Shares Outstanding 352.91M
Market Cap 5.04B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout

Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout

Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity.

Amarin Dives on Surprise FDA Heart-Drug Review

Amarin Dives on Surprise FDA Heart-Drug Review

Shares of Amarin plunge after the biotech company's surprise revelation that the Food and Drug Administration will hold an advisory panel review of its heart drug Vascepa.

Amarin (AMRN) Alert: Johnson Fistel Launches Investigation Into Amarin Corporation Plc; Investors Encouraged To Contact Firm

Amarin (AMRN) Alert: Johnson Fistel Launches Investigation Into Amarin Corporation Plc; Investors Encouraged To Contact Firm

SAN DIEGO, Aug. 9, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Amarin Corporation plc ("Amarin") (NASDAQ: AMRN) for violations of federal securities laws.

Follow These Leaders: Cramer's 'Mad Money' Recap (Wednesday 7/31/19)

Follow These Leaders: Cramer's 'Mad Money' Recap (Wednesday 7/31/19)

Jim Cramer tallies July's leaders and says the Fed may be just an afterthought when you look at why some stocks -- like Apple -- are winning.

Roku, Colgate-Palmolive, Amarin: 'Mad Money' Lightning Round

Roku, Colgate-Palmolive, Amarin: 'Mad Money' Lightning Round

Jim Cramer weighs in on Roku, Colgate-Palmolive, Amarin, Albemarle, Banco Santander, Simulations Plus and more.

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Jim Cramer weighs in on Planet Fitness, Allergan, Amarin, MPLX, Zynerba Pharmaceuticals, Schnieder National, United Parcel Service and more.

This Is a Short Term Trading Market

This Is a Short Term Trading Market

This is not the time to make a big directional call.

S&P Logs Record Close as Markets Shrug Off U.S.-EU Trade Dispute Worries

S&P Logs Record Close as Markets Shrug Off U.S.-EU Trade Dispute Worries

Stocks surge into close with the Dow Jones Industrial Average ending slightly higher and the S&P 500 at a new record amid a fresh U.S.-EU tariff dispute.

Amarin Surges on Revenue Guidance Boost

Amarin Surges on Revenue Guidance Boost

Amarin surges after the pharmaceutical company boosts its revenue guidance amid strong demand for its Vascepa chronic cardiovascular treatment.

HP, Mercadolibre, Bausch Health: 'Mad Money' Lightning Round

HP, Mercadolibre, Bausch Health: 'Mad Money' Lightning Round

Jim Cramer takes a look at HP, Mercadolibre, Bausch Health, ArcelorMittal, Johnson & Johnson, Transdigm Group, PPL Corp. McKesson and more.

An Interesting Small-Cap on My Radar This Morning Is Coda Octopus

An Interesting Small-Cap on My Radar This Morning Is Coda Octopus

I added shares this morning and will be looking for more entry points as it develops.

Stocks Take Flight on Dovish Fed Comments

Stocks Take Flight on Dovish Fed Comments

Market players are trying to decipher Fed Chair Powell's latest words.

Downgrades Are Important: Cramer's 'Mad Money' Recap (Monday 4/8/19)

Downgrades Are Important: Cramer's 'Mad Money' Recap (Monday 4/8/19)

Jim Cramer says these downgrades may be well-reasoned, but he wants to know if they're correct.

Ollie's Bargain Outlet, Novo Nordisk, Avnet: 'Mad Money' Lightning Round

Ollie's Bargain Outlet, Novo Nordisk, Avnet: 'Mad Money' Lightning Round

Jim Cramer weighs in on Ollie's Bargain Outlet, Novo Nordisk, Avnet, Cabot Corp., Helmerich & Payne, Amarin, Golar LNG, Nio and more.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has...

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

Market players are more skeptical of the quick moves on U.S.-China trade news.

Lyft's Aggressive IPO Pricing Was a Mistake

Lyft's Aggressive IPO Pricing Was a Mistake

Poor trading action in Lyft will likely create some distrust of upcoming IPOs, and Uber in particular.

The Best Approach to Trading Lyft

The Best Approach to Trading Lyft

Valuation and all the other issues that are being discussed are secondary to the price action.

Amarin Jumps After Diabetes Association Adds Drug to Its 'Must Have' List

Amarin Jumps After Diabetes Association Adds Drug to Its 'Must Have' List

The American Diabetes Association adds Amarin's Vascepa drug to its standard of care recommendation list.

Market Gains Some Momentum, Lululemon Breaks Out

Market Gains Some Momentum, Lululemon Breaks Out

While there is some positive movement, it has not been sustained which makes trading quite tricky.

The Market Worries About Global Growth but Looks for Progress on China Trade

The Market Worries About Global Growth but Looks for Progress on China Trade

China negotiations resume today and the potential for weekend news is high.

Alibaba and Amarin Among Unanimous Strong Buy Stocks

Alibaba and Amarin Among Unanimous Strong Buy Stocks

You know a stock is doing well when the all market's best analysts are bullish.

AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact The Firm About Their Rights

AMARIN ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact The Firm About Their Rights

Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (NASDAQ: AMRN).

Robbins Arroyo LLP: Amarin Corporation Plc (AMRN) Sued For Misleading Shareholders

Robbins Arroyo LLP: Amarin Corporation Plc (AMRN) Sued For Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Amarin Corporation plc (NASDAQ: AMRN) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between September 24,...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company") (NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has...

Glancy Prongay & Murray LLP Reminds Investors Of The Deadline In The Class Action Lawsuit Against Amarin Corporation Plc (AMRN)

Glancy Prongay & Murray LLP Reminds Investors Of The Deadline In The Class Action Lawsuit Against Amarin Corporation Plc (AMRN)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the April 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN)...

AMARIN INVESTOR ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact The Firm About Their Rights

AMARIN INVESTOR ALERT: Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact The Firm About Their Rights

Gibbs Law Group filed the only class action lawsuit to date against Amarin Corporation (NASDAQ: AMRN).

TheStreet Quant Rating: D (Sell)